RESEARCH PROJECTS

3D Scaffold-Mediated In Situ Programming of T-Cells for Immunotherapy of Solid Tumors

This research explored the design and application of biomaterial-based 3D scaffolds to revolutionize cancer immunotherapy. These scaffolds were engineered to be implanted directly into the tumor site, where they created a localized microenvironment that activated and programmed T-cells in situ.

By delivering immune-modulating factors and presenting bioactive signals, the scaffolds enhanced T-cell proliferation, activation, and functionality, enabling precise targeting and destruction of solid tumor cells. This approach overcame key challenges in traditional immunotherapies, such as poor T-cell infiltration and off-target effects, offering a highly localized and personalized treatment strategy. The project integrated principles of biomaterials science, immunology, and tissue engineering to pave the way for next-generation cancer therapies.

Design and Fabrication of a Bilayered Bioactive Dermal Patch with Enhanced Wound Healing Properties

This project centered on creating an advanced bilayered bioactive dermal patch aimed at improving wound healing, particularly for chronic and complex wounds. The patch was designed with two functional layers: a robust structural layer that offered mechanical support and protected the wound site, and a bioactive layer infused

with therapeutic agents to stimulate cell migration, proliferation, angiogenesis, and extracellular matrix remodeling. Inspired by the natural architecture of skin, this patch created an optimal microenvironment for tissue regeneration while preventing infections and minimizing scarring. The integration of cutting-edge biomaterials and sustained release of bioactive molecules ensured accelerated healing and enhanced tissue functionality. This innovation holds significant potential for advancing regenerative medicine and transforming wound care treatments.

Development of a 3D Biomimetic System to Investigate Cancer Cell Behavior in the Context of Diabetic Conditions

This research project developed a sophisticated 3D biomimetic system to study the unique behaviors of cancer cells under diabetic conditions. Diabetes was known to alter the tumor micro-environment, influencing cancer progression, metastasis, and response to therapies. Traditional 2D models failed to capture the complex interplay between cancer cells, stromal components, and altered biochemical signals in diabetic settings.

To address this, a 3D culture system was designed to replicate key features of the diabetic tumor microenvironment, incorporating advanced biomaterials, extracellular matrix components, and diabetes-mimicking metabolic conditions. This platform allowed for the study of cancer cell proliferation, invasion, and drug resistance in a physiologically relevant context. Insights gained from this system provided a deeper understanding of cancer-diabetes interactions and aided in the development of tailored therapeutic strategies for cancer patients with co-existing diabetic conditions.

Isolation and Differentiation of Dendritic Cells from Human PBMCs for Precision Allergen Testing

This project focused on developing a robust platform for isolating and differentiating dendritic cells (DCs) from human peripheral blood mononuclear cells (PBMCs) to improve the precision of allergen testing. Dendritic cells are key players in the immune system, acting as antigen-presenting cells that initiate and regulate immune responses.

By leveraging their unique ability to identify and process allergens, this research created a reliable model for personalized allergen evaluation. The project involved optimizing protocols for isolating PBMCs and differentiating them into functional dendritic cells in vitro. These DCs were then exposed to specific allergens to study their activation patterns, cytokine secretion profiles, and T-cell interaction dynamics. This approach enabled the identification of individual immune responses to allergens, providing insights into mechanisms of hypersensitivity and tolerance.

Formulation of Dendritic Cell-Based Vaccines Loaded with Antigen and Adjuvant for Immunotherapy of Solid Tumors

This project focused on the development of dendritic cell (DC)-based vaccines as a targeted immunotherapy for solid tumors. Dendritic cells, the most potent antigen-presenting cells of the immune system, play a critical role in initiating and regulating anti-tumor immune responses. By harnessing their unique ability to process and present tumor antigens, this research

created a therapeutic platform to enhance T-cell-mediated immunity against solid tumors. The project involved isolating and differentiating dendritic cells from patient-derived peripheral blood mononuclear cells (PBMCs). These DCs were then loaded ex vivo with tumor-specific antigens and adjuvants to enhance their maturation and immunogenicity. Once reintroduced into the patient, the modified DCs were designed to activate cytotoxic T-lymphocytes, effectively targeting and eliminating tumor cells.

Development of Silver Nanoparticle-Loaded Antiviral Masks for COVID-19

This project focused on the design and fabrication of antiviral masks enhanced with silver nanoparticles to provide an added layer of protection against COVID-19 and other respiratory pathogens. Silver nanoparticles are known for their antimicrobial properties, which make them effective in inactivating viruses and bacteria on contact. The research involved embedding silver nanoparticles into the fabric of masks to continuously release antimicrobial ions, thereby preventing the growth and transmission of pathogens.

These masks were engineered to maintain high filtration efficiency while providing durable, long-lasting protection against viral particles. The project aimed to develop a practical and scalable solution to mitigate the spread of COVID-19, improving the safety and effectiveness of personal protective equipment in public and healthcare settings.

Biomaterial-Based Loco-Regional Delivery of CAR T-Cells for Advanced Solid Tumor Immunotherapy

This project explored the integration of biomaterials with CAR T-cell therapy to overcome challenges in treating advanced solid tumors. While CAR T-cells showed remarkable success in hematological malignancies, their efficacy against solid tumors was often limited by poor infiltration, immunosuppressive tumor microenvironments, and off-target effects.

To address these limitations, the research focused on developing biomaterial-based platforms for the precise, loco-regional delivery of CAR T-cells directly to tumor sites. The approach involved engineering biocompatible scaffolds and hydrogels capable of encapsulating CAR T-cells and releasing them in a controlled manner. These biomaterials were designed to provide a protective niche for T-cell survival, enhance their expansion, and maintain their functionality within the hostile tumor microenvironment.

Development of Non-Viral Gene Delivery Vectors for Precision Engineering of T-Cells

This project aimed to design and optimize non-viral gene delivery systems for precise genetic modification of T-cells, enabling advanced immunotherapy applications. Non-viral vectors offer a safer, more scalable alternative to viral methods, reducing the risks of insertional mutagenesis and immunogenicity while maintaining high efficiency.

The research focused on engineering biomaterial-based delivery platforms, such as nanoparticles and lipid-based carriers, to transfer therapeutic genes into T-cells with high specificity and minimal off-target effects. These vectors were tailored to enhance transfection efficiency, protect genetic material, and ensure controlled gene expression, facilitating the development of T-cell therapies for cancer, autoimmune diseases, and other conditions.

Cloning and Development of a Plasmid System for the Expression of Chicken Ovalbumin as an Antigen Target in Cancer Immunotherapy

This project focused on engineering a plasmid system to express chicken ovalbumin (OVA) as a model antigen for studying cancer immunotherapy. OVA is widely used in immunological research to evaluate antigen presentation, immune activation, and tumor-specific responses. The plasmid was designed for efficient expression of OVA in mammalian systems, enabling the development and testing of antigen-specific

immune therapies. This research provided a versatile tool for investigating mechanisms of tumor immunology, optimizing antigen-targeting strategies, and advancing preclinical models for personalized cancer immunotherapy.

Hiren Dandia